Dopamine D(2) receptor blockade in schizophrenia.
Bressan
R A
RA
Jones
H M
HM
Ell
P J
PJ
Pilowsky
L S
LS
D014150:Antipsychotic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001549:Benzamides; D010054:Brief Psychiatric Rating Scale / Q000706:statistics & numerical data; D003863:Depression / Q000139:chemically induced / Q000175:diagnosis / Q000378:metabolism; D065127:Dopamine D2 Receptor Antagonists; D006801:Humans; D007457:Iodine Radioisotopes; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D018967:Risperidone / Q000493:pharmacokinetics / Q000627:therapeutic use; D012559:Schizophrenia / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D015899:Tomography, Emission-Computed, Single-Photon / Q000706:statistics & numerical data
D014150:Antipsychotic Agents; D001549:Benzamides; D065127:Dopamine D2 Receptor Antagonists; D007457:Iodine Radioisotopes; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D018967:Risperidone